IP Library › Granted Patent US 8,193,237
Granted Patent B2
US 8,193,237 · App. 12/448,826 · Granted Jun 5, 2012

Indole derivative having IκB kinase β inhibitory activity

Assignee: Santen Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,193,237
App. No.
12/448,826
Granted
Jun 5, 2012
Kind
B2
Abstract

Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R 1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R 2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

Claims (154)

1. A compound represented by the following formula (1) or a salt thereof:

wherein R 1 represents a hydrogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, an aryl group which is unsubstituted or substituted by a substituent, a hydroxy group, or a lower alkoxy group which is unsubstituted or substituted by a substituent;

R 2 represents a halogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, a lower alkenyl group which is unsubstituted or substituted by a substituent, a lower alkynyl group which is unsubstituted or substituted by a substituent, —X 1 —COR 3 , —X 1 —COOR 3 , —X 1 —CONR a R b , —X 1 —SR 3 , —X 1 —NR a R b , —X 1 —NHCO—R 3 , —X 1 —CN, —X 1 —N 3 , or a group represented by the following formula (2)

wherein X 1 represents a single bond, a lower alkylene group which is unsubstituted or substituted by a substituent, a lower alkenylene group which is unsubstituted or substituted by a substituent, or a lower alkynylene group which is unsubstituted or substituted by a substituent;

R 3 represents a hydrogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, or a lower alkenyl group which is unsubstituted or substituted by a substituent;

R a and R b are the same or different and each represents a hydrogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, a lower alkenyl group which is unsubstituted or substituted by a substituent, a lower alkoxy group which is unsubstituted or substituted by a substituent, a lower alkylsulfonyl group which is unsubstituted or substituted by a substituent, or an arylsulfonyl group which is unsubstituted or substituted by a substituent;

X 2 represents a single bond, a lower alkylene group which is unsubstituted or substituted by a substituent, a lower alkenylene group which is unsubstituted or substituted by a substituent, a lower alkynylene group which is unsubstituted or substituted by a substituent, —X 3 —CO—, —X 3 —CONH—, —X 3 —S—, —X 3 —NH—, —X 3 —NHCO—, or —X 3 —NHCONH—;

X 3 represents a single bond, a lower alkylene group which is unsubstituted or substituted by a substituent, a lower alkenylene group which is unsubstituted or substituted by a substituent, or a lower alkynylene group which is unsubstituted or substituted by a substituent,

the ring A represents a hydrocarbon ring or a heterocyclic ring;

R 4 represents a halogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, —X 4 —OR 5 , —X 4 —OCOR 5 , —X 4 —COR 5 , —X 4 —COOR 5 , —X 4 —CONR c R d , —X 4 —SR 5 , —X 4 —SOR 5 , —X 4 —SONR c R d , —X 4 —SO 2 R 5 , —X 4 —SO 2 NR c R d , —X 4 —NR c R d , —X 4 —NHCOR 5 , —X 4 —HCOOR 5 , —X 4 —NHSOR 5 , —X 4 —NHSO 2 R 5 , —X 4 —CN, or —X 4 —NO 2 ;

X 4 represents a single bond, a lower alkylene group which is unsubstituted or substituted by a substituent, or a lower cycloalkylene group which is unsubstituted or substituted by a substituent;

R 5 represents a hydrogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, a lower cycloalkyl group which is unsubstituted or substituted by a substituent, or an aryl group which is unsubstituted or substituted by a substituent;

R c and R d are the same or different and each represents a hydrogen atom, a lower alkyl group which is unsubstituted or substituted by a substituent, a lower cycloalkyl group which is unsubstituted or substituted by a substituent, an aryl group which is unsubstituted or substituted by a substituent, or a heterocyclic group which is unsubstituted or substituted by a substituent; or

R c and R d are joined to each other to form a monocyclic saturated heterocyclic ring which is unsubstituted or substituted by a substituent;

m represents 0, 1, 2, 3, or 4, provided that R 2 is the same or different when m is 2, 3, or 4; and

n represents 0, 1, 2, 3, or 4, provided that R 4 is the same or different when n is 2, 3, or 4.

2. The compound or a salt thereof according to claim 1 , wherein, in the formula (1),

R 1 represents a hydrogen atom, a lower alkyl group, an aryl-lower alkyl group, an aryl group, a nitroaryl group, a hydroxy group, a lower alkoxy group, or an aryl-lower alkoxy group;

R 2 represents a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, a lower alkenyl group, a halogeno-lower alkenyl group, a lower alkynyl group, a halogeno-lower alkynyl group, —X 1 —COR 3 , —X 1 —COOR 3 , —X 1 —CONR a R b , —X 1 —SR 3 , —X 1 —NR a R b , —X 1 —NHCO—R 3 , —X 1 —CN, —X 1 —N 3 , or a group represented by the following general formula (2):

wherein X 1 , represents a single bond, a lower alkylene group, a lower alkenylene group, or a lower alkynylene group;

R 3 represents a hydrogen atom, a lower alkyl group, a halogeno-lower alkyl group, an aryl-lower alkyl group, a heterocyclic lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a cyano lower alkyl group, a lower alkenyl group, a halogeno-lower alkenyl group, an aryl-lower alkenyl group, a heterocyclic lower alkenyl group, a hydroxy lower alkenyl group, a lower alkoxy lower alkenyl group, or a cyano lower alkenyl group;

R a and R b are the same or different and each represents a hydrogen atom, a lower alkyl group, an aryl-lower alkyl group, a heterocyclic lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a cyano lower alkyl group, a lower alkenyl group, an aryl-lower alkenyl group, a heterocyclic lower alkenyl group, a hydroxy lower alkenyl group, a lower alkoxy lower alkenyl group, a cyano lower alkenyl group, a lower alkoxy group, an aryl-lower alkoxy group, a heterocyclic lower alkoxy group, a hydroxy lower alkoxy group, a lower alkoxy lower alkoxy group, a cyano lower alkoxy group, a lower alkylsulfonyl group, or an aryl sulfonyl group;

X 2 represents a single bond, a lower alkylene group, a lower alkenylene group, a lower alkynylene group, —X 3 —CO—, —X 3 —CONH—, —X 3 —S—, —X 3 —NH—, —X 3 —NHCO—, or —X 3 —NHCONH—;

X 3 represents a single bond, a lower alkylene group, a lower alkenylene group, or a lower alkynylene group;

the ring A represents a hydrocarbon ring or a heterocyclic ring;

R 4 represents a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, —X 4 —OR 5 , —X 4 —OCOR 5 , —X 4 —COR 5 , —X 4 —COOR 5 , —X 4 —CONR c R d , —X 4 —SR 5 , —X 4 —SOR 5 , —X 4 —SONR c R d , —X 4 —SO 2 R 5 , —X 4 —SO 2 NR c R d , —X 4 —NR c R d , —X 4 —NHCOR 5 , —X 4 —NHCOOR 5 , —X 4 —NHSOR 5 , —X 4 —NHSO 2 R 5 , —X 4 —CN, or —X 4 —NO 2 ;

X 4 represents a single bond, a lower alkylene group, or a lower cycloalkylene group;

R 5 represents a hydrogen atom, a lower alkyl group, halogeno-lower alkyl group, a lower cycloalkyl lower alkyl group, an aryl-lower alkyl group, a lower cycloalkyl group, or an aryl group;

R c and R d are the same or different and each represents a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkyl group having —NR e R f as a substituent, a lower cycloalkyl group, a lower alkyl lower cycloalkyl group, an aryl group, a lower alkylaryl group, a heterocyclic group, or a lower alkyl heterocyclic group; or

R c and R d are joined to each other to form a monocyclic saturated heterocyclic ring;

R e and R f are the same or different and each represents a hydrogen atom or a lower alkyl group; or

R e and R f are joined to each other to form a monocyclic saturated heterocyclic ring;

m represents 0, 1, 2, 3, or 4, provided that R 2 is the same or different when m is 2, 3, or 4; and

n represents 0, 1, 2, 3, or 4, provided that R 4 is the same or different when n is 2, 3, or 4.

3. The compound or a salt thereof according to claim 1 , wherein, in the formula (1),

R 1 represents a hydrogen atom, a lower alkyl group, an aryl-lower alkyl group, a nitroaryl group, or a hydroxy group;

R 2 represents a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, a lower alkenyl group, a lower alkynyl group, —X 1 —COR 3 , —X 1 —COOR 3 , —X 1 —CONR a R b , —X 1 —SR 3 , —X 1 —NR a R b , —X 1 —NHCO—R 3 , —X 1 —CN, —X 1 —N 3 , or a group represented by the following formula (2):

wherein X 1 represents a single bond, a lower alkylene group, a lower alkenylene group, or a lower alkynylene group;

R 3 represents a hydrogen atom, a lower alkyl group, a halogeno-lower alkyl group, an aryl-lower alkyl group, a heterocyclic lower alkyl group, a hydroxy lower alkyl group, a cyano lower alkyl group, or a lower alkenyl group;

R a and R b are the same or different and each represents a hydrogen atom, a lower alkyl group, an aryl-lower alkyl group, a heterocyclic lower alkyl group, a hydroxy lower alkyl group, a cyano lower alkyl group, a lower alkenyl group, a lower alkoxy group, or an arylsulfonyl group;

X 2 represents a single bond, a lower alkylene group, a lower alkenylene group, a lower alkynylene group, —X 3 —CO—, —X 3 —CONH—, —X 3 —S—, —X 3 —NH—, —X 3 —NHCO—, or —X 3 —NHCONH—;

X 3 represents a single bond, a lower alkylene group, a lower alkenylene group, or a lower alkynylene group;

the ring A represents a hydrocarbon ring or a heterocyclic ring;

R 4 represents a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, , —X 4 —OR 5 , —X 4 —OCOR 5 , —X 4 —COR 5 , —X 4 —COOR 5 , —X 4 —CONR c R d , —X 4 —SO 2 R 5 , —X 4 —SO 2 NR c R d , —X 4 —NR c R d , —X 4 —NHCOR 5 , —X 4 —NHCOOR 5 , —X 4 —NHSO 2 R 5 , —X 4 —CN, or —X 4 —NO 2 ;

X 4 represents a single bond, a lower alkylene group, or a lower cycloalkylene group;

R 5 represents a hydrogen atom, a lower alkyl group, halogeno-lower alkyl group, an aryl-lower alkyl group, or an aryl group;

R c and R d are the same or different and each represents a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a lower alknxy lower alkyl group, a lower alkyl group having —NR e R f as a substituent, a lower cycloalkyl group, a heterocyclic group, or a lower alkyl heterocyclic group; or

R c and R d are joined to each other to form a monocyclic saturated heterocyclic ring;

R e and R f are the same or different and each represents a hydrogen atom or a lower alkyl group; or

R e and R f are joined to each other to form a monocyclic saturated heterocyclic ring;

m represents 0, 1, or 2, provided that R 2 is the same or different when m is 2; and

n represents 0, 1, 2, 3, or 4, provided that R 4 is the same or different when n is 2, 3, or 4.

4. The compound or a salt thereof according to claim 1 , wherein, in the formula (1),

R 1 represents a hydrogen atom, a lower alkyl group, an aryl-lower alkyl group, a nitroaryl group, or a hydroxy group;

R 2 represents a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, a lower alkenyl group, a lower alkynyl group, —X 1 —COOR 3 , —X 1 —SR 3 , —X 1 —NR a R b , —X 1 —NHCO—R 3 , or a group represented by the following formula (2):

wherein X 1 represents a single bond, a lower alkylene group, or a lower alkynylene group;

R 3 represents a hydrogen atom, a lower alkyl group, or an aryl-lower alkyl group;

R a and R b are the same or different and each represents a hydrogen atom or a lower alkyl group;

X 2 represents a single bond, a lower alkylene group, a lower alkynylene group, —X 3 —NHCO—, or —X 3 —NHCONH—;

X 3 represents a single bond;

the ring A represents a hydrocarbon ring or a heterocyclic ring;

R 4 represents a halogen atom, a lower alkyl group, —X 4 —OR 5 , —X 4 —NR c R d , —X 4 —NHSO 2 R 5 , —X 4 —CN, or —X 4 —NO 2 ;

X 4 represents a single bond or a lower alkylene group;

R 5 represents a hydrogen atom or a lower alkyl group;

R c and R d are the same or different and each represents a hydrogen atom, a lower alkyl group, a lower alkyl group having —NR e R f as a substituent, or a lower cycloalkyl group; or

R c and R d are joined to each other to form a monocyclic saturated heterocyclic ring;

R e and R f are the same or different and each represents a hydrogen atom or a lower alkyl group; or

R e and R f are joined to each other to form a monocyclic saturated heterocyclic ring;

m represents 0, 1, or 2, provided that R 2 is the same or different when m is 2; and

n represents 0, 1, or 2, provided that R 4 is the same or different when n is 2.

5. The compound or a salt thereof according to claim 1 , wherein the ring A is a hydrocarbon ring.

6. The compound or a salt thereof according to claim 5 , wherein the hydrocarbon ring is selected from the group consisting of cyclopropane, cyclopentane, cyclohexane, cyclohexene, adamantane, benzene, and naphthalene.

7. The compound or a salt thereof according to claim 5 , wherein the hydrocarbon ring is selected from the group consisting of cyclohexane and benzene.

8. The compound or a salt thereof according to claim 1 , wherein the ring A is a heterocyclic ring.

9. The compound or a salt thereof according to claim 8 , wherein the heterocyclic ring is selected from the group consisting of pyrrolidine, pyrrolidone, pyrrole, imidazole, pyrazole, indole, pyridine, pyrimidine, quinoline, furan, benzofuran, thiophene, benzothiophene, isoxazole, thiazole, morpholine, thiomorpholine, dioxaborane, and dithiolane.

10. The compound or a salt thereof according to claim 8 , wherein the heterocyclic ring is selected from the group consisting of pyrrolidine, pyrrole, indole, pyridine, quinoline, furan, thiophene, and dithiolane.

11. A compound or a salt thereof selected from the group consisting of

2-Aminocarbonylamino-6-bromo-1-hydroxyindole-3-carboxamide,

2-Aminocarbonylamino-5-methylindole-3-carboxamide,

6-Acetylamino-2-aminocarbonylaminoindole-3-carboxamide,

2-Aminocarbonylamino-6-benzoylaminoindole-3-carboxamide,

2-Aminocarbonylamino-6-(3-phenylureido)indole-3-carboxamide,

2-Aminocarbonylamino-6-dimethylaminoindole-3-carboxamide,

2-Aminocarbonylamino-6-(pyrrolidin-1-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(pyrrol-1-yl)indole-3-carboxamide,

2-Aminocarbonylaminoindole-3-carboxamide,

2-Aminocarbonylamino-6-bromo-7-methylindole-3-carboxamide,

2-Aminocarbonylamino-6-trifluoromethylindole-3-carboxamide,

2-Aminocarbonylamino-6-methoxycarbonylindole-3-carboxamide,

2-Aminocarbonylamino-6-bromoindole-3-carboxamide,

2-Aminocarbonylamino-6-(4-fluorophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-phenylindole-3-carboxamide,

2-Aminocarbonylamino-6-(3-methoxyphenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(thiophen-2-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(pyridin-3-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(2-fluorophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-fluorophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-cyanophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-nitrophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-methylsulfonylaminophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(thiophen-3-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(furan-2-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(furan-3-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(2-chlorothiophen-3-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(quinolin-3-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-vinylindole-3-carboxamide,

2-Aminocarbonylamino-6-[(E)-3-methoxy-1-propenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-(indol-5-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-[(E)-1-pentenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-(4-dimethylaminophenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(furan-3-yl)-7-methylindole-3-carboxamide,

2-Aminocarbonylamino-6-(pyrrol-2-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-[3-(2-hydroxyethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-(pyridin-4-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(4-hydroxymethyl-3-methoxyphenyl)indole 3-carboxamide,

2-Aminocarbonylamino-6-(2-chloropyridin-4-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-[(1R)-3-(1-hydroxyethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-[(1S)-3-(1-hydroxyethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-(4-aminomethylphenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-[4-(1-aminoethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-[4-(1-amino-1-methylethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-phenylethynylindole-3-carboxamide,

2-Aminocarbonylamino-6-(3-hydroxy-1-propynyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-dimethylamino-1-propynyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-ethynylindole-3-carboxamide,

2-Aminocarbonylamino-6-ethylindole-3-carboxamide,

2-Aminocarbonylamino-6-(4-hydroxybutyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-dimethylaminopropyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-methoxypropyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-hydroxymethylphenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(5-hydroxymethylfuran-2-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(3-isopropylaminomethylphenyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-[3-(2-hydroxyethylaminomethyl)phenyl]indole-3-carboxamide,

2-Aminocarbonylamino-6-(5-cyclopropylaminomethylfuran-2-yl)indole -3-carboxamide,

2-Aminocarbonylamino-6-(5-methylaminomethylthiophen-2-yl)indole -3-carboxamide,

2-Aminocarbonylamino-6-hydroxymethylindole-3-carboxamide,

2-Aminocarbonylamino-6-(1,3-dithiolan-2-yl)indole-3-carboxamide,

2-Aminocarbonylamino-6-(pyrrolidin-1-ylcarbonyl)indole-3-carboxamide,

2-Aminocarbonylamino-6-benzylaminocarbonylindole-3-carboxamide,

2-Aminocarbonylamino-6-(pyrrolidin-1-ylmethyl)indole-3-carboxamide, and

2-Aminocarbonylamino-6-ethylthiomethylindole-3-carboxamide.

12. A pharmaceutical composition comprising (i) as an active ingredient the compound or a salt thereof according to claim 1 and (ii) a pharmaceutical carrier.

13. An IKKβ inhibitor comprising as an active ingredient the compound or a salt thereof according to claim 1 .

14. The pharmaceutical composition according to claim 12 , which is a therapeutic agent for age-related macular degeneration.

15. The pharmaceutical composition according to claim 12 , which is a therapeutic agent for diabetic retinopathy or diabetic macular edema.

16. The pharmaceutical composition according to claim 12 , which is a therapeutic agent for keratitis, conjunctivitis, or uveitis.

17. The pharmaceutical composition according to claim 12 , which is a therapeutic agent for glaucoma.

18. The pharmaceutical composition according to claim 12 , which is a therapeutic agent for rheumatoid arthritis.

19. A method for inhibiting IKKβ comprising administering to a patient in need thereof a pharmacologically effective amount of the compound or a salt thereof according to claim 1 .

20. A method for treating age-related macular degeneration comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a salt thereof according to claim 1 .

21. A method for treating diabetic retinopathy or diabetic macular edema comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a salt thereof according to claim 1 .

22. A method for treating keratitis, conjunctivitis, or uveitis comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a salt thereof according to claim 1 .

23. A method for treating glaucoma comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a salt thereof according to claim 1 .

24. A method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a salt thereof according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2009
From: ENOMOTO, HIROSHI; KAWASHIMA, KENJI; KUDOU, KAZUHIRO; YAMAMOTO, MINORU; MURAI, MASAAKI; INABA, TAKAAKI; ISHIZAKA, NORIKO
To: SANTEN PHARMACEUTICAL CO., LTD.
Reel/Frame 022952/0684 →
Priority Claims (1)
JP 2007-005554 · Jan 15, 2007 · national
Continuity (1)
Related Publication 20100041628A1 · Feb 18, 2010